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The ability to control neural activity is essential for research not only in basic
neuroscience, as spatiotemporal control of activity is a fundamental
experimental tool, but also in clinical neurology for therapeutic brain
interventions. Transcranial-magnetic, ultrasound, and alternating/direct
current (AC/DC) stimulation are some available means of spatiotemporal
controlled neuromodulation. There is also light-mediated control, such as
optogenetics, which has revolutionized neuroscience research, yet its clinical
translation is hampered by the need for gene manipulation. As a drug-based
light-mediated control, the effect of a photoswitchable muscarinic agonist
(Phthalimide-Azo-Iper (PAI)) on a brain network is evaluated in this study.
First, the conditions to manipulate M2 muscarinic receptors with light in the
experimental setup are determined. Next, physiological synchronous
emergent cortical activity consisting of slow oscillations—as in slow wave
sleep—is transformed into a higher frequency pattern in the cerebral cortex,
both in vitro and in vivo, as a consequence of PAI activation with light. These
results open the way to study cholinergic neuromodulation and to control
spatiotemporal patterns of activity in different brain states, their transitions,
and their links to cognition and behavior. The approach can be applied to
different organisms and does not require genetic manipulation, which would
make it translational to humans.
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1. Introduction
All perceptions, memories, and behaviors
are based on the communication between
the billions of neurons that constitute the
brain.[1–4] Individual neurons transmit in-
formation using chemical and electrical sig-
nals, and are organized in groups or cir-
cuits involved in different functions.[3,5,6]
The electrochemical interactions of neu-
ronal ensembles result in electrical activ-
ity emerging from the brain, which can
show synchrony across populations in the
form of brain rhythms and waves that
propagate[7–9] or asynchronous discharges,
depending on the brain state.[10] Differ-
ent brain states (slow wave sleep, REM,
wakefulness, anesthesia, etc.) are associated
with specific network activity parameters
such as brain rhythms of certain frequency
and synchronization across areas or partic-
ular functional connectivity patterns, while
brain states are also associated with spe-
cific behaviors.[1,11] Transitions across brain
states are therefore linked to substantial
changes in brain activity patterns.[12] For ex-
ample, deep sleep is dominated by large and
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synchronous brain waves, which transition towards a more
desynchronized and higher-frequency content with waking
up.[8,13,14] These changes in brain and behavioral states and the
concomitant changes in electrophysiological activity are physi-
ologically driven largely by neuromodulators, of which acetyl-
choline (ACh) is one.[12,15] Indeed, it is known that the activation
of cholinergic nuclei in the upper brainstem contributes to the
transition from sleep to awake states[16–18] and associated brain
patterns.[19] However, it is not fully understood how the different
cells expressing ACh receptors contribute to the alteration of the
global cortical state, or what the contribution of different mus-
carinic receptor subtypes to this transition is.
Cholinergic receptors include ionotropic nicotinic ion chan-
nels and muscarinic metabotropic G protein-coupled receptors.
They modulate brain activity, and in particular the activity of
the cerebral cortex,[20] being involved in crucial neocortical func-
tions such as attention,[21–23] learning,[24–26] memory,[27] as well
as sensory and motor functions.[28–30] In the neocortex, ACh is
released mostly at cholinergic terminals from neurons with so-
mas in the basal forebrain nuclei. Electrical stimulation of the
nucleus basalis can evoke the release of ACh in the neocortex, al-
though in an unselective manner, as ascending projections from
basal forebrain nuclei not only comprise cholinergic axons, but
also GABAergic and glutamatergic axons.[31]
Selective stimulation of cholinergic projections in the neocor-
tex from basal forebrain nuclei has been demonstrated with op-
togenetics and has enabled the disruption of neocortical syn-
chronous activity during certain sleep states.[13] Optogenetic
stimulation of basal forebrain cholinergic neurons also revealed
their influence in awake cortical dynamics: cholinergic neuro-
modulation was found to be relevant for visual discrimination
tasks, modulating the encoding properties of V1 neurons and ac-
tivating cortical transitions faster than previously presumed.[13]
However, optogenetics cannot target endogenous signaling as it
is limited by the overexpression of microbial proteins using ge-
netic manipulation, which can distort synaptic physiology.[32,33]
It also raises safety and regulatory concerns regarding therapeu-
tic applications.[32] Illumination can be applied locally with im-
planted devices like optical fibers and LEDs, or transcranially
when using long wavelengths, which are less scattering and more
penetrating in tissue.[34,35]
The control of neuronal signaling with photopharmacology is
based on synthetic ligands that target endogenous proteins, and
thus its physiological relevance spans from circuit to sub-cellular
levels. Since neuronal receptors are highly conserved, photo-
switchable ligands can generally be used in multiple species, and
their safety and regulation can be established in the same man-
ner as other drugs. Given that the cholinergic system is key to
the modulation of a variety of Central Nervous System (CNS)
functions,[20,36] the use of selective and photoswitchable cholin-
ergic drugs to achieve a spatiotemporal modulation of cortical
activity might have relevant scientific and clinical implications.
We recently developed a photoswitchable agonist of M2 mus-
carinic acetylcholine receptors (mAChRs), Phthalimide-Azo-Iper
(PAI),[37] but its action on neuronal circuits and networks has
never been explored.
Herein, we report that the cholinergic-dependent brain
state transitions in the neocortex can be controlled and thus
investigated in detail with light using photosensitive drugs.
In particular, we have found that PAI enables the modulation
of spontaneous emerging slow oscillations (SO) in neuronal
circuits. PAI cis-to-trans photoisomerization decreases the Down
state durations and increases oscillatory frequency in cortical
slices. In addition, PAI allows the reversible manipulation of the
cortical oscillatory frequency in anesthetized mice using light.
Two different species, ferret (in vitro) and mouse (in vivo) were
used in this study, since ferret cortical slices are more suitable
than those of rodents to spontaneously generating network
activity under physiological conditions.[38] Thus, we demon-
strate that photopharmacology allows us to selectively control
SO both in vitro and in vivo, opening the way for the analysis
of their spatiotemporal dynamics and their effects on brain
and behavioral state transitions. Photoactivation of mAChR
driven by PAI offers the potential to modulate neural circuits
in numerous regions distributed throughout the neocortex. In
this first work we studied the impact of global activation on the
temporal dynamics of cortical patterns. Patterned illumination
will allow us to carry out more spatially targeted studies in the
future.
In our design, we considered that changes in cortical rhythms
accompany behavioral state transitions, and endogenous ACh
actions play a central role in such variations.[11,39–46] It is
known[16–18] that ACh contributes to the shift of the neocor-
tical network state from synchronous to asynchronous activ-
ity (associated with awake states), thus we hypothesized that
a preparation expressing synchronized activity—physiological
slow oscillations—would be an appropriate testbed to investigate
the effect of muscarinic ligands, including the novel photosensi-
tive agonist PAI.
2. Results
2.1. Non-Specific Activation of mAChRs Evokes Neuronal
Hyperexcitability in Cortical Slices
We started by studying the effect of Iperoxo, a muscarinic non-
selective agonist,[47,48] on cortical SO spontaneously generated in
cortical slices. The goal was to evaluate the potential of mAChRs
to modulate the dynamics of the neocortical network, while avoid-
ing the simultaneous activation of nicotinic cholinergic receptors
(nAChRs).[20] In addition, these experiments would allow the val-
idation of whether Iperoxo-based photoswitches like PAI could
be useful photopharmacological tools to control neuronal activ-
ity, and characterizing their performance.
Ferret cortical slices spontaneously generate cortical SO,[38]
a hallmark of activity during deep sleep or anesthesia.[38] We
recorded this spontaneous oscillatory activity (control) and then
the activity under different concentrations (1, 10, 100 × 10–9
m; n = 7) of Iperoxo. Slow oscillations consist of alternating
periods of activity or high neuronal firing (Up states) and
periods of near silence (Down states). In order to quantify
Up and Down state duration, firing rates and frequencies, we
estimated the MUA (multiunit activity reflecting the activity
of the local neuronal population) and ran an algorithmic sep-
aration of Up and Down states by establishing a threshold
from a bimodal distribution of MUA that separates firing
periods (Up states) from silent periods (Down states).[7] A
more detailed account of this quantification can be found in
the Experimental Section. The activation of mAChRs by Iper-
oxo resulted in a global change in the network’s dynamics
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Figure 1. Activation of mAChRs with non subtype-specific agonist Iperoxo (IPX) evokes neuronal hyperexcitability in cortical slices. A) On the left, the
experimental setup: 16-channel multielectrode array (MEA); WM, white matter; L1-L6, layer 1–6. On the right, raw local field potential (LFP) traces
illustrating network activity showing the increase in oscillatory frequency corresponding to the spectrogram of panel B with 100 × 10–9m IPX. B)
Spectrogram from the same time recording of LFP traces on panel A: control, 100 × 10–9 m and periods of seizure-like discharges. C) Oscillatory
frequency (Hz) and FR (a.u.) during the Up-states in control (ctrl) conditions and after IPX (1, 10, 100 × 10–9 m; n = 7 ferret brain slices). Muscarinic
activation of the brain slice with 100 × 10–9m IPX produces a significant increase in oscillatory frequency compared to control conditions, and no
significant changes in the firing rate (FR) during Up-states. Data are reported as mean ± standard error of mean (SEM). Analyses were performed with
one-way ANOVA test (Brown–Forsythe and Welch test, unpaired t with Welch’s correction). *p-value <5 × 10−2. D) Averaged power spectral density
(PSD) of oscillatory activity showing low (<1 Hz), delta (1–4 Hz) and alpha (7–12 Hz) frequency component.
in a dose-dependent way, displaying enhanced excitability
(Figure 1A,B). At 100 × 10–9 m Iperoxo, the oscillatory
frequency—or frequency of the Up/Down state cycle—
significantly increased (from 0.85 ± 0.1 Hz in the control to
1.42 ± 0.18 Hz with 100 × 10–9 m Iperoxo, p-value = 3 × 10−2),
while the firing rate (FR; see Experimental Section)[49] during
Up-states did not change significantly (from 0.97 ± 0.15 a.u.
to 0.74 ± 0.09 a.u. with 100 × 10–9 m Iperoxo) (Figure 1C). At
concentrations equal or higher than 100 × 10–9 m Iperoxo, the
oscillatory activity evolved to periods of full-blown epileptiform
discharges (Figure 1A,B), as previously characterized in this
preparation[49] and also described in vivo following muscarinic
activation,[50,51] as in the pilocarpine model of epilepsy.[52] Such
epileptiform or seizure-like discharges are a clear sign of hy-
perexcitability, displaying intense firing for several seconds and
long periods of silence, and characterized by a rather different
spectrogram showing larger amplitudes in different frequency
bands: slow (<1 Hz), delta (1–4 Hz), and alpha (7–12 Hz)
frequency components, and including enhancement of beta
(12–30 Hz) and gamma frequencies (30–100 Hz) (Figure 1D).
However, our interest was to avoid epileptiform discharges and
to activate muscarinic receptors within the range of physiological
activity, therefore with the activation achieved below 100 × 10–9
m Iperoxo.
2.2. Effect of PAI Isomers on Slow and Fast Oscillations In Vitro
The hyperexcitable network state induced with Iperoxo reflects
the impact of mAChR activation on cortical networks and brain
states.[14] In order to remotely control these states, we aimed at
the muscarinic neuromodulation with light using PAI, a photo-
switchable Iperoxo-derivative that allows the reversible activation
of M2 mAChRs in vivo.[37] The light-dependent behavior of PAI
is achieved with a molecular switch in its structure that is based
on azobenzene. PAI exists in two forms, trans and cis, which are
in dynamic equilibrium with each other (Figure 2A). A distribu-
tion of 87% in favor of the trans form (13% of the cis) is found in
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Figure 2. Effect on SO of mAChRs activation by trans-PAI (dark-relaxed)
and cis-PAI (pre-illuminated with UV). A) Chemical structures of trans- and
cis-PAI. B) Subtype selectivity of trans-PAI (3, 10 × 10–12 m) was studied
by comparing the amplitude of fluorescence calcium imaging responses of
cells expressing M1 (3 × 10–12m, n = 232 cells; 10 × 10–12 m, n = 232 cells;
IPX, n = 258) or M2-GqTOP (3 × 10–12m, n = 70 cells; 10 × 10–12m, n =
200 cells; IPX, n = 300) mAChRs, using the procedure described in Riefolo
et al. 2019[37] and by pre-incubating cells with OGB-1AM (10 × 10–6m
for 30 min) as calcium indicator. M2 mAChR transfected cells gave a sig-
nificantly higher response than M1 mAChR expressing cells (33% for M2
compared to 8% for M1). Data were normalized over the maximum re-
sponse obtained with the nonselective orthosteric agonist IPX in satura-
tion conditions at 30 × 10–12m. These results in cell lines are in agreement
with previous reports (Riefolo et al., 2019),[37] in which higher concen-
trations were required for cardiac assays in vivo. Bars are mean ± SEM
and compared using a t-test of two samples assuming equal variances.
the dark or after illumination with visible light (white light (WL)
for 2 min). After illumination with ultraviolet (UV) light (365 nm
for 1 min) the ratio between the two configurations rapidly
changes to about 77% cis (23% trans). Both PAI isomeric mixtures
(respectively termed “trans” and “cis” for simplicity) are thermally
stable for hours and their biological effects have been character-
ized in vitro and in vivo.[37] Despite the partial photoconversion
(which is characteristic of azobenzene-based switches) the trans-
and the cis-enriched forms of PAI display different pharmaco-
logical activity: the trans configuration is a more potent activa-
tor of M2 receptors than the cis, allowing the reversible manip-
ulation of muscarinic functions with light over many cycles.[37]
Prior to testing PAI in the brain, which shows high expression
of both M1 and M2 receptors, we tested its activity profile in
these two mAChR subtypes using in vitro GTPgammaS assays
(Figure S1.2, Supporting Information) and calcium imaging as-
says (Figure 2B) in cultured cell lines separately overexpressing
M1 and M2 receptors. Our results show significant M2 selectiv-
ity (Figure 2B) in agreement with the dualsteric design and in
vivo properties of PAI.[37] M2 receptors are highly expressed in
cardiac tissue and in the brain, where they play a relevant role in
several CNS disorders.[36] Controlled spatiotemporal regulation
of M2 mAChR activity and subsequent effects on cortical neu-
ronal networks may provide new therapeutic opportunities for
diseases involving the cholinergic system. Note that subtype se-
lectivity can be advantageous to interpret (photo)pharmacological
experiments but muscarinic activation with light is sufficient for
the aim of this work. We applied PAI to spontaneously active
neocortical brain slices and recorded their oscillatory activity be-
fore and after photoactivating the drug. We first obtained dose-
response curves of the two drug forms separately, trans- (dark-
adapted state) and cis-PAI (pre-illuminated with UV light) with
the purpose of identifying the concentration range displaying dif-
ferences in brain activity with light. The baseline activity (charac-
terized by SO) was recorded as a control, prior to bath-application
of artificial cerebrospinal fluid (ACSF) with increasing PAI con-
centrations (10 × 10–9 m, 100 × 10–9 m, 300 × 10–9 m, and 1 ×
10–6 m, n = 6 ferret brain slices for each PAI form, trans and cis)
(Figure 2C). Both trans-PAI and cis-PAI significantly modulated
the Up- and Down-state sequence in a dose-dependent manner,
with cis-PAI displaying weaker effects in agreement with the re-
ported PAI properties in cells expressing M2 receptors[37] (Fig-
ure 2C,D,E; the quantification and significance versus control for
*p < 5 × 10−3. C) Raw local field potential (LFP) example recordings show-
ing the different ability of trans- and cis-PAI to increasing the oscillatory
frequency. Note that trans-PAI is a stronger agonist of M2 mAChR than cis-
PAI.[37] D) Raster plots showing the FR during the Up-states (color coded)
under control conditions and different trans- and cis-PAI concentrations.
E) oscillatory frequency (Hz) and FR during the Up-states (a.u.) of the
two different PAI isomers, trans- (blue, n = 6 ferret brain slices) and cis-
PAI (pink, n = 6 ferret brain slices) at different concentrations. Data are
reported as mean ± SEM. Analyses were performed with multiple t-test
(Mann-Whitney). Significant differences between cis- and trans-PAI (**p-
value < 10−2) are observed in the oscillatory frequency at 100 × 10–9 m
and in the FR at 1 × 10–6 m. These experiments are aimed at estimat-
ing the concentration of effective photoswitching of cortical oscillations,
which was set at 200 × 10–9 m in subsequent experiments (see Figures 3
and 4).
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Figure 3. Photocontrol of brain waves in vitro using PAI and direct illumination with white light. A) Representative local field potential (LFP) traces
(top) and raster plots of firing rate (FR) during the Up-states under control conditions, 200 × 10–9 m of cis-PAI and 200 × 10–9 m trans-PAI after
photoconversion with white light (WL) (n = 17 ferret slices) (bottom). B) Representative spectrogram under control condition, 200 × 10–9 m of cis-PAI
and 200 × 10–9 mtrans-PAI (WL). C) Oscillatory frequency (Hz) and FR during the Up-states (a.u.) at 200 × 10–9 m PAI after pre-illumination with
365 nm (cis-PAI), and photoswitching with WL (trans-PAI). Data are reported as mean ± SEM. Analyses were performed with one-way ANOVA test
(Brown–Forsythe and Welch test, unpaired t with Welch’s correction). **p-value < 10–2; ***p-value < 10–3, ****p-value < 10–4. D) Averaged power
spectral density (PSD) of oscillatory activity under control conditions, 200 × 10–9 m of cis-PAI and 200 × 10–9 mtrans-PAI after WL activation (color
code).
each isomer are detailed in Figure S2, Supporting Information).
The differences between cis-PAI and trans-PAI were significant
for the oscillatory frequency at 100 × 10–9 m and for the FR dur-
ing Up-states at 1 × 10–6 m (Figure 2E). Note that epileptiform
activity was never observed with PAI up to concentrations of 1 ×
10–6 m, in contrast to the effect of Iperoxo.
These results obtained with a limited number of animals for
each isomer (n = 6) already suggested that intermediate concen-
trations between 100 and 300 × 10–9 m might be suitable to pro-
duce changes in the oscillatory frequency and in the firing rate
of the Up-states upon cis-trans photoisomerization (Figure 2E).
Thus, in subsequent experiments with light we expanded the
sample (n = 17) and focused on the concentration of 200 × 10–9
m in order to photomodulate cortical SO using PAI.
2.3. Photoswitchable PAI Effectively Modulates Cortical Slow
Oscillations In Vitro
Once the concentration range of drug to obtain different oscilla-
tory activity evoked by cis- and trans-PAI was determined in vitro
(Figure 2), we moved on to control the rhythmic activity with
light in cortical slices (Figure 3). We took advantage of the ther-
mal stability of both PAI forms to apply initially the less potent
one (cis-PAI) at 200 × 10–9 m in cortical slices (n = 17), in the
absence of WL to avoid photoconversion to trans-PAI during the
recordings.[37] As shown in Figure 3, 200 × 10–9 m cis-PAI evoked
an increment of the oscillatory frequency (from 0.53 ± 0.04 Hz in
the control to 1.04 ± 0.14 Hz with cis-PAI, p-value = 2.8 × 10−3),
and no significant effects in the FR of the Up-states (from 0.98 ±
0.09 a.u. in the control to 0.86 ± 0.10 a.u. with cis-PAI, p-value =
2.9 × 10−1) in comparison to the control situation (Figure 3A,C).
Subsequent direct illumination of the slices with WL produced
a robust increase in oscillatory frequency (from 0.53 ± 0.04 Hz
in the control to 1.68 ± 0.13 upon illumination, p-value < 10−4;
from 1.04 ± 0.14 Hz with cis-PAI to 1.68 ± 0.13 upon illumina-
tion, p-value = 1.1 × 10−3), a significant decrease in FR of the
Up-states (from control values of 0.98 ± 0.09 a.u. to 0.52 ± 0.06
a.u. upon illumination, p-value = 2 × 10−4; from 0.86 ± 0.10 a.u.
with cis-PAI to 0.52 ± 0.06 a.u. upon illumination, p-value = 2.2
× 10−3), and a noticeable change in the activity regime of the net-
work (Figure 3A,C). The changes in the power spectrum in the
population were incremental, as illustrated in Figure 3B,D. These
differences are in agreement with PAI photoconversion to the ac-
tive form (trans). At this stage, the modulation of cortical activity
was not reversible upon illumination with 365 nm light (to iso-
merize PAI to the cis form in situ) in slices, which could be due
either to pharmacological irreversibility (which was ruled out in
experiments in vivo, see next Section 2.4) or to the reduced pen-
etration of UV light in brain tissue.
2.4. Photoswitchable PAI Can Reversibly Modulate Brain Wave
Activity In Vivo
Having established the unique ability of PAI to alter cortical os-
cillatory activity with light in slices, we then aimed at obtaining
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Figure 4. In vivo photomodulation of brain waves. A) Representative raw traces of local field potential (LFP) (top, in mV) and multiunit activity (bottom,
in arbitrary units), showing the differences in oscillatory frequency and firing rate (FR) during the Up-states between the control, 1 x 10–6 m cis-PAI
(pre-illuminated with 365 nm), and trans-PAI after photoswitching with white light (WL). B) Individual (left) and mean (right) quantification of oscil-
latory frequency (Hz) (n = 8 mice), showing a significant increase upon illuminating cis-PAI with WL. Data are reported as mean ± SEM. Analyses
were performed with one-way ANOVA test (repeated measures [RM], Geisser–Greenhouse correction—no sphericity—and uncorrected Fisher’s LSD).
**p-value < 10–2; ***p-value < 10–3, ****p-value < 10–4. *p-value < 5 × 10−2. C) The mean quantification of FR during the Up-states (a.u.) is not sig-
nificantly affected by illumination of cis-PAI (n = 8). D) Averaged power spectral density (PSD) of oscillatory activity at different concentrations displays
significant enhancement at delta, theta, alpha, and gamma frequency bands after WL activation (left). Mean ± SEM quantification of PSD from D-left
panel (n = 8) (right). Analyses were performed with Friedman test and the Wilcoxon post-hoc tests corrected for multiple comparisons. *p-value <
5 × 10−2.
a proof of concept of photocontrolling the cortical state in vivo.
Cortical activity was recorded from C57BL6/JR mice (n = 8) with
an electrode inserted through a craniotomy across which we used
to carry out the drug application and brain illumination (see Ex-
perimental Section). Initially, we induced deep anesthesia in the
animals, a state that is known to reproduce the slow wave sleep
state,[7,41,53] and which is characterized by the generation of corti-
cal SO similar to the slow frequency waves observed in our exper-
iments in slices under control conditions (Figures 1–3).[7] Such
SO activity in anesthetized mice was recorded for 500 s under WL
illumination of the brain, and the characteristic parameters ob-
tained (oscillatory frequency 0.60 ± 0.05 Hz, FR during the Up-
states 0.80 ± 0.11 a.u.) were taken as the baseline, control con-
dition in vivo. A 100 µL drop of 1 × 10–6 m cis-PAI solution was
initially applied to the brain surface in the absence of WL, to avoid
cis to trans photoisomerization of PAI. The oscillatory frequency
was not significantly altered by cis-PAI (0.58 ± 0.06 Hz) (Figure
4B), while it caused only a minor increase in the FR during the
Up-states (0.86 ± 0.14 a.u.) (Figure 4C). Subsequent illumination
with WL significantly increased the oscillatory frequency (from
0.60 ± 0.05 Hz in the control to 0.73 ± 0.06 Hz upon illumina-
tion, p = 2.8 × 10−2) (Figure 4B), and induced an increment of the
delta (p = 1.6 × 10−2) and gamma (p = 2.3 × 10−2) frequencies
band compared with control conditions (Figure 4D), while the
FR during Up states was decreased to the control values (0.83 ±
0.09 a.u., Figure 4C). This light-dependent increase in oscillatory
frequency activity of PAI in vivo is in partial agreement with the
in vitro results observed in ferret slices, which also displayed a
reduction in FR (Figure 3). The difference may be due to the in-
tegrity of the neural network and the cholinergic activity in vivo.
In brain cortical sections the effect of trans-PAI is not re-
versible using 365 nm light and we aimed to understand whether
this was due to muscarinic activation mechanisms or just to the
limited tissue penetration of UV wavelengths, which could hin-
der isomerization in deeper regions. The illumination of the mice
brain using a more powerful 365 nm source (100 W bulb, see
Experimental Section) did not significantly reduce the oscilla-
tory frequency from the trans-PAI-excited situation (n = 4, Fig-
ure S4A, Supporting Information). Since tissue scattering can-
not be avoided at this wavelength we tried to revert the effect of
trans-PAI by outcompeting it by direct application of its cis iso-
mer, which binds to the same receptor site with similar strength
that trans (see competition binding experiments, Figure S1.1,
Supporting Information) but causes weaker or no activation. For
Adv. Sci. 2021, 2005027 © 2021 The Authors. Advanced Science published by Wiley-VCH GmbH2005027 (6 of 11)
www.advancedsciencenews.com www.advancedscience.com
this purpose, we significantly increased the oscillatory frequency
with 200 × 10–9 m trans-PAI, and then applied 1 × 10–6 m cis-
PAI. Indeed, we observed the return to the control-like oscillatory
activity (n = 4, Figure S4BC, Supporting Information), demon-
strating that the process is pharmacologically reversible and that
the lack of reversibility is probably due to the limited penetra-
tion of UV light. Thus, the optimization of both the light delivery
system and/or drug photophysical properties (e.g., photoswitch-
ing at less scattering wavelengths) have the potential to reversibly
photocontrol neural muscarinic actions in vivo.
3. Discussion
Different brain states are associated with distinct brain emer-
gent patterns and behaviors. In order to establish strong causal
links between them, neural activity must be manipulated and
recorded to observe the effects on specific behaviors. Pharma-
cological tools have proven very useful but they affect brain
waves in a systemic way and have relatively slow dynamics.[54]
Thus, understanding the mechanisms of brain and behavioral
state transitions requires new techniques to manipulate neuronal
activity[1] that enable the neural modulation of specific brain re-
gions and neuronal circuits in a fast and reversible way. They can
be defined by a multimodal stimulation approach (e.g., electrical
stimulation with implanted microelectrodes), photostimulation
with cell-specific optogenetics[55–58] and with neurotransmitter-
specific photopharmacology.[59]
Electromagnetic stimulation pioneered the noninvasive mod-
ulation of brain activity and is used therapeutically to treat CNS
diseases.[60] For example, transcranial alternating current stimu-
lation has been applied to modulate alpha and beta waves in the
motor cortex[61] and transcranial magnetic stimulation has been
used to modulate gamma oscillations in the prefrontal cortex.[62]
However, further improvements are required to enhance their
spatiotemporal and spectral performance, both for fundamen-
tal research and therapeutic purposes.[60] Optogenetics[55–58] has
emerged as an alternative to electromagnetic stimulation, al-
lowing the activation or inhibition of specific cell populations.
For example, photocontrolling the release of ACh, which mod-
ulates the transitions between different brain states,[12,15] can be
achieved by overexpressing photosensitive proteins in choliner-
gic neurons of mice neocortex.[13,63] However, genetic manipu-
lation is required in this approach, limiting so far its usability
in humans.[32] The photopharmacological approach presented
here is, to date, the only way to directly photomodulate brain
state transitions in intact tissue. We first studied the effect of
the muscarinic agonist Iperoxo[47] on isolated cortical slices (Fig-
ure 1) in order to demonstrate that a slow oscillatory state can be
controlled by selectively manipulating muscarinic receptors (in-
cluding all M1–M5 subtypes) at their physiological location and
context. The oscillatory frequency of the network was increased
with 100 × 10–9 m Iperoxo, eventually leading to seizure-like dis-
charges, in agreement with the outcome of muscarinic stimu-
lation using knockout mice and the pilocarpine-induced model
of epilepsy.[50,51] Photocontrol of muscarinic signaling was sub-
sequently achieved in vitro and in vivo with the photochromic
Iperoxo derivative PAI[37] (Figures 2–4). We showed that PAI is
selective for M2 versus M1 subtype receptors and thus it only ac-
counts for part of the effects of Iperoxo. In the experiments of
Figure 2, PAI was pre-illuminated in order to administer the in-
active cis form, which is then stable over hours at 37 °C. This
allowed us to compare the activities of both forms at different
concentrations and identifying 200 × 10–9 m PAI as a suitable
concentration for direct photoswitching of cortical activity in vitro
(Figure 3) and in vivo (Figure 4). Overall, this proof-of-concept
demonstration of photocontrol of brain waves has allowed us to
identify two important limitations of PAI that will be addressed
in future drug designs. Namely, that PAI is active in the dark and
that it is not readily photo-reversible in brain tissue due to the
limited penetration of UV light. We have promising evidence that
both limitations can be overcome, respectively using a “bridged”
azobenzene to obtain a dark-inactive analog drug with equiva-
lent pharmacology,[64] and using tissue-penetrating infrared light
from a pulsed laser.[37] Other aspects of PAI that can be opti-
mized include its activation wavelength under non-pulsed illu-
mination, photosensitivity, reversibility, photoswitchable concen-
tration range (“therapeutic window”), safety profile, and perme-
ability to the blood-brain barrier. Still, as a small molecule, PAI
is less likely to trigger adverse immune responses than the over-
expression of microbial opsins.[32,65] M2 mAChRs are involved
in several CNS diseases like major depressive[36,66] and bipolar
disorders,[36,67] Parkinson’s[36,68] and Alzheimer’s[36,68] diseases,
but also in alcohol, smoking, and drug dependence.[36,69] These
disorders are thus susceptible to drug-based photomodulation
in vivo without requiring genetic manipulation. We envisage
that once a suitable drug concentration has been determined
for optimal photoswitching, spatiotemporal patterns of stimula-
tion can be applied to ask specific questions. For example, how
does a focal, acute activation propagate in space and time? What
is the behavioral outcome? How does it interfere with the on-
going (endogenous) wave activity? How does the size, duration,
and location of the activated region relate to the behavioral out-
come and its reversibility? Beyond the fundamental understand-
ing of the mechanisms of brain waves, if these experiments could
be performed with safe photoswitchable drugs and using non-
invasive transcranial illumination, these questions would gain
great clinical relevance and feasibility. Beyond photoswitchable
muscarinic agonists, these concepts could be also exploited with
drug-like antagonists (Riefolo et al, in review) and adrenergic
ligands[70] among many others, eventually allowing us to build
3D functional pharmacological charts that could be correlated
with anatomical maps.
In summary, the manipulation of brain state transitions, by
means of photocontrolling the frequency of cortical oscillations,
has been achieved with a photoswitchable dualsteric agonist of
M2 mAChRs. This result opens the way to: a) dissecting the
spatiotemporal distribution and pharmacology of brain states,
namely mapping how they depend on agonists, antagonists, and
modulators of the different muscarinic subtypes expressed in the
CNS; and b) investigating the neuronal dynamics and causality
that regulate brain state transitions in the cerebral cortex and be-
yond. In particular, two-photon stimulation of PAI using pulsed
infrared light[37] should enable deep penetration and subcellular
resolution in 3D,[71] as recently demonstrated with endogenous
mGlu5.
[72] Compared to the local and often inhomogeneous ex-
pression patterns achieved with viral injections of optogenetic
constructs, diffusible small molecules like PAI can in principle be
applied to larger brain regions to control neuronal oscillations.[73]
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Thus, remote control of brain waves based on the photophar-
macological manipulation of endogenous muscarinic receptors
may reveal the complex 3D molecular signaling underlying brain
states and their transitions, in order to link them with cognition
and behavior in a diversity of wild-type organisms.
4. Conclusion
A method for directly manipulating neural activity and brain
rhythms with light-controlled drugs is demonstrated. It is based
on a photoswitchable muscarinic small molecule and does not
require gene therapy. The photocontrol of endogenous receptors
and their functions in the central nervous system, such as the
transition between different brain states, is an achievement for
neuromodulation technologies that is useful as a tool in basic
neuroscience research and in future brain therapies and stimu-
lation. Thus, photopharmacological neuromodulation combined
with implantable optoelectronic devices offers the ability to ex-
ploit the untapped potential of neuropharmacology, by control-
ling drug action in precise spatiotemporal patterns.
5. Experimental Section
Slice Preparation: For the in vitro experiments the authors used iso-
lated cortical slices from ferret, because they robustly reproduce the corti-
cal SO compared with other animal models.[74] Twenty-seven ferrets (4- to
6-months-old) were anesthetized with sodium pentobarbital (40 mg kg−1)
and decapitated. The entire forebrain was rapidly removed and placed in
oxygenated cold (4–10 °C) bathing medium.[75] Ferrets were treated in ac-
cordance with protocols approved by the Animal Ethics Committee of the
University of Barcelona, which comply with the European Union guide-
lines on the protection of vertebrates used for experimentation (Directive
2010/63/EU of the European Parliament and the Council of 22 September
2010). Coronal slices (400 µm thick) from primary visual cortex (V1) were
used.[76] To increase tissue viability the authors used a modification of the
sucrose-substitution technique,[77] such that during slice preparation, the
tissue was placed in a solution in which NaCl was replaced with sucrose
while maintaining the same osmolarity. After preparation, the slices were
placed in an interface-style recording chamber (Fine Sciences Tools, Foster
City, CA, USA). During the first 30 min the cortical slices were superfused
with an equal mixture in volume of the normal bathing medium, artificial
cerebral spinal fluid (ACSF), and the sucrose-substituted solution. Follow-
ing this, normal bathing medium was added up to the recording cham-
ber and the slices were superfused for 1–2 h; the normal bathing medium
contained (in mm): NaCl, 126; KCl, 2.5; MgSO4, 2; Na2HPO4, 1; CaCl2, 2;
NaHCO3, 26; dextrose, 10; and was aerated with 95% O2, 5% CO2 to a
final pH of 7.4. Then, a modified slice solution was used throughout the
rest of the experiment; it had the same ionic composition except for dif-
ferent levels of the following (in mm): KCl, 4; MgSO4, 1; and CaCl2, 1.
[75]
Bath temperature was maintained at 34–36 °C.
Drug Application and Photostimulation in Brain Slices: Iperoxo and PAI,
both prepared as previously reported from commercially available starting
materials[37] were bath-applied at the concentrations range of 1 to 100 ×
10–9 m for Iperoxo and 10 × 10–9 m to 1 × 10–6 m for PAI, as discussed
in the Results section. The authors typically waited more than 1000 s after
the application of the drug in order to let it act, to obtain a stable pat-
tern of electrical activity, and to ensure a stable concentration in the bath,
this being an interface chamber. PAI effectively photomodulates the ac-
tivity of M2 receptors in vitro and in vivo: its dark-adapted state (trans
form) behaves as a strong M2 agonist, then upon illumination with UV
light (365 nm), PAI switches to its less active state (cis form). PAI can be
switched back to its “full on-state” with WL, or using two-photon excita-
tion with pulsed near-infrared light.[37] The high thermal stability of PAI
cis form allows the administration of the less active drug (inactive in the
cerebral cortex at concentrations lower than 1 × 10–6 m) and subsequent
activation of M2 receptors in the target region with WL.[37] The authors
first investigated the efficacy of PAI in cortical neuronal circuits in vitro by
obtaining the dose-response curves of trans- and cis-PAI solutions applied
separately. The more active PAI isomer (trans) was tested by applying its
dark-adapted form (87% of trans-PAI), and cis-PAI was obtained by illumi-
nating 1 mm stock solutions with 365 nm light (77% of cis-PAI, which is
the maximum that can be achieved at the photo stationary state). Because
of the high concentration of the stock solution (1 mm) and for the sake of
having the maximal possible photoconversion of PAI into the cis form, UV
light irradiation (Vilber Lourmat Dual Wave Length UV Lamps, 365 nm 6
W) was performed over 10 min, even if it was demonstrated that the max-
imal percentage of the cis can be reached by a shorter time exposure to
UV light (2 min).[37] Increasing concentrations of both trans- and cis-PAI
(10 × 10–9 m, 100 × 10–9 m, 300 × 10–9 m, and 1 × 10–6 m) were bath
applied in order to build up the dose-response curves.
LFP Recording and Data Analysis from In Vitro Recordings: The authors’
objective in this study was to identify the modulation of network dynam-
ics exerted by photoswitchable muscarinic agonists. To this end, they ob-
tained multiple LFP recordings and their correspondent multiunit activity
(MUA) in the way described below. No single units were identified since
they aimed at capturing the dynamics of the population and not of indi-
vidual neurons. The recordings started after allowing at least 2 h of re-
covery of the slices. Extracellular recordings were obtained with flexible
arrays of 16-electrodes arranged in columns as in Figure 1A. The multi-
electrode array (MEA) covered a large part of the area occupied by a cor-
tical slice.[78] It consisted of six groups of electrodes positioned to record
electrophysiological activity from superficial and from deep cortical lay-
ers (692 µm apart) and from what should correspond to three different
cortical columns (1500 µm apart). The unfiltered field potential (raw sig-
nal) was acquired at 10 kHz with a Multichannel System Amplifier (MCS,
Reutlingen, Germany) and digitized with a 1401 CED acquisition board
and Spike2 software (Cambridge Electronic Design, Cambridge, UK). The
MUA was estimated from the power of the frequencies between 200 and
1500 Hz in 5 ms windows.[7,49] The spectrum in this frequency band is
a good estimate of the firing of the neuronal population, since it is pro-
portional to the density of the Fourier components at high frequencies.[79]
The MUA signal values were logarithmically scaled to compensate for the
high fluctuations in the firing of neurons that are very close to the elec-
trode, thus obtaining the logMUA signal (which the authors refer to as
firing rate; FR). A bimodal distribution of the MUA the two peaks of the
distribution corresponded to the samples of the activity network belonging
to the Up and Down state, respectively. Thus, a threshold value separating
the two modes of the distribution was set between the two peaks, such that
samples belonged to the Up or to the Down states depending on their po-
sition with respect to this threshold. After Up and Down state detection,
mean Up and Down state durations were obtained.[7] The frequency of
the SO was the inverse of the duration of the entire Up–Down cycle. The
Up state detection necessary was performed by setting a threshold in the
log(MUA) time series as previously described to quantify frequency of the
SO.[7,49] Firing rate (FR) of the Up states was quantified from the trans-
formed log(MUA) signal as mean of absolute value of log(MUA). To study
the variability of power spectral densities (PSD) of the local field potential
(LFP), the authors used Welch’s method with 50% overlapped Hamming
window with a resolution of 1 Hz. All off-line estimates and analyses were
implemented in MATLAB (The MathWorks Inc., Natick, MA, USA). All vari-
ables in the experimental conditions were compared with the control (no
chemical added) condition.
The In Vivo Preparation: Cortical electrophysiology experiments were
carried out in 2–3-month-old C57BL6/JR mice (n = 8) in accordance with
the European Union Directive 2010/63/EU and approved by the local
ethics committee. Mice were kept under standard conditions (room tem-
perature, 12:12-h light-dark cycle, lights on at 08:00 a.m.). Anesthesia was
induced by intraperitoneal injection of ketamine (30 mg kg−1) and medeto-
midine (100 mg kg−1). After this procedure, the mouse was placed in a
stereotaxic frame, and air was enriched with oxygen. Body temperature
was maintained at 37 °C throughout the experiment.[7] A craniotomy was
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performed in each mouse: AP −2.5 mm, L 1.5 mm (primary visual cor-
tex, V1).[80] Cortical recordings were obtained from infragranular layers
with 1–2 MΩ single tungsten electrode insulated with a plastic coating ex-
cept for the tip (FHC, Bowdoin, ME, USA). Spontaneous LFP recordings
from the V1 area provided information about the local neuronal popula-
tion activity—within 250 µm.[81] MUA estimation, Up-state detection and
quantification of relative FR was performed as previously described. All
these parameters were used to compare spontaneous activity during anes-
thesia (control), after application of the pre-illuminated less active drug
form (cis-PAI) and drug activation with WL (trans-PAI). Cis-PAI was locally
delivered to the cerebral cortex surface and activity was recorded while ap-
plying a commercial red filter on the WL source to avoid the activation of
the drug. The uncovered brain was illuminated from a 3 cm distance with
a WL source (Photonic Optics Optics Cold Light Source LED F1) in order
to activate the drug in situ (trans-PAI). The trans-to-cis photoconversion
was performed by illuminating the brain from a 5 cm distance with a very
powerful 365 nm lamp (Spectroline, Spectronics FC-100-F, 230 V, 365 nm,
100 W Spot Bulb) in order to improve the penetration of light into the tis-
sues. The electrophysiological signal was amplified with a multichannel
system (Multi Channel Systems), digitized at 20 kHz with a CED acqui-
sition board, and acquired with Spike 2 software (Cambridge Electronic
Design) unfiltered.[82]
In Vitro Specific M1 and M2 Muscarinic Agonist Functional Assays: Sub-
type selectivity of trans-PAI was studied by comparing the amplitude of
fluorescence calcium imaging responses of cells expressing M2-GqTOP
and M1 mAChRs. Human M2-GqTOP mAChR was transfected as de-
scribed in Riefolo et al. 2019.[37] Human M1 mAChR (Addgene) was trans-
fected with X-tremeGENE 9 DNA Transfection Reagent (Roche Applied
Science) following the manufacturer’s instructions. The day after trans-
fection, cells were harvested with accutase (Sigma-Aldrich) and seeded
onto 16-mm glass coverslips (Fisher Scientific) pretreated with collagen
(Sigma-Aldrich) to allow cell adhesion. Preconfluent cultures were used
for experiments between 48 and 72 h after transfection. In vitro single-
cell calcium imaging was performed as described in Riefolo et al. 2019,[37]
pre-incubating cells with OGB-1AM (10 × 10–6 m for 30 min) as calcium
indicator. The subtype selectivity of 3 and 10 × 10–12 m trans-PAI emerged
by comparing the amplitude of fluorescence calcium imaging responses
of cells expressing M1 (3 × 10–12 m, n = 232 cells; 10 × 10–12 m, n = 232
cells; IPX, n = 258) or M2-GqTOP (3 × 10–12 m, n = 70 cells; 10 × 10–12 m,
n = 200 cells; IPX, n = 300) mAChRs. Cells transfected with M2 mAChR
gave significantly higher responses than M1 mAChR expressing cells (33%
for M2 compared to 8% for M1). Data were normalized over the maximum
response obtained with the nonselective agonist Iperoxo (IPX) at saturat-
ing concentration of 30 × 10–12 m (t-test of two samples assuming equal
variances. p = 1.58 × 10−3).
A preliminary comparison between mAChR subtypes was obtained us-
ing an in vitro muscarinic agonist functional assay (Eurofins GTPgammaS
assay) which allows us to estimate possible activation of M1 and M2 re-
ceptors (as expressed in the Eurofins specifications). In particular, differ-
ent concentrations of the active isomer trans-PAI were tested on human
recombinant M1 and M2 receptors expressed in CHO-K1 (Chinese ham-
ster ovary) cells. Compound agonism is defined by quantitation measured
of bound [35S]GTP𝛾S. PAI was preincubated with 0.045 mg ml−1 mem-
branes and 3 × 10–6 m GDP for 30 min at 30 °C in modified HEPES buffer
pH 7.4 with SPA beads are added for another 60 min at 30 °C. The reac-
tion is then initiated by the addition of 0.3 × 10–9 m [35S]GTP𝛾S for 30
min. Trans-PAI-induced increase of [35S]GTP𝛾S binding by 50% or more
(≥50%) relative to 1 × 10–9 m (M1) or 1 × 10–6 m (M2) oxotremorine M
responses indicates possible M1 or M2 agonist activity, as indicated in the
Eurofins assay specifications. Experiments were performed in duplicates
(n = 2) and were accepted in accordance with Eurofins Quality Control
Unit’s validation standard operating procedure.
Statistical Analysis: In vitro and in vivo oscillatory frequency, firing rate
(FR) during the Up-state, PSD of oscillatory activity values are reported as
mean± SEM. All the oscillatory frequency and FR during the Up-state anal-
yses in brain slices of Iperoxo (IPX), PAI dose-response curves, and 200 ×
10–9 m PAI photoconversion experiments were performed with one-way
ANOVA test (Brown-Forsythe and Welch test, unpaired t with Welch’s cor-
rection) of GraphPad Prism 9. The analyses in brain slices between trans-
and cis-PAI oscillatory frequency and FR during the Up-state values were
performed with multiple t-test (Mann-Whitney) of GraphPad Prism 9. All
the in vivo statistical analyses of oscillatory frequency and firing rate (FR)
during the Up-state were performed with one-way ANOVA test (repeated
measures [RM], Geisser–Greenhouse correction—no sphericity—and un-
corrected Fisher’s LSD) of GraphPad Prism 9. PSD statistical analysis in
vivo was performed with Friedman test and the Wilcoxon post-hoc tests
corrected for multiple comparisons of MATLAB R2020b. Calcium imaging
analyses of 3 and 5 independent cell preparations expressing M1 and M2-
GqTOP mAChRs, respectively, were first normalized over the basal fluo-
rescence of the cells. The fluorescence amplitudes of cellular PAI-induced
calcium oscillations were normalized over IPX responses at the saturating
concentration of 30 × 10–12 m, reported as mean ± SEM, and compared
using a t-test of two samples (assuming equal variances) using Origin Pro
8.5.
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